Max
07-20-2004, 07:21 AM
AGY Therapeutics Licenses Product Candidate From M's Science for Phase 2 Clinical Development
Tuesday July 20, 7:31 am ET
Deal Validates AGY's Technology Platform, Which Enabled Discovery of Novel Target for Functional Recovery After Stroke
SOUTH SAN FRANCISCO, Calif. and KOBE, Japan, July 20 /PRNewswire/ -- AGY Therapeutics Inc., a privately held biotechnology company, and M's Science Corporation, a privately held drug discovery and development company, announced today that AGY has obtained from M's Science the exclusive rights to develop and commercialize a sigma receptor agonist compound, AGY-94806, also known as M's Science compound SA4503, which AGY plans to study initially for enhancement of functional recovery after stroke.
http://biz.yahoo.com/prnews/040720/sftu022_1.html
Tuesday July 20, 7:31 am ET
Deal Validates AGY's Technology Platform, Which Enabled Discovery of Novel Target for Functional Recovery After Stroke
SOUTH SAN FRANCISCO, Calif. and KOBE, Japan, July 20 /PRNewswire/ -- AGY Therapeutics Inc., a privately held biotechnology company, and M's Science Corporation, a privately held drug discovery and development company, announced today that AGY has obtained from M's Science the exclusive rights to develop and commercialize a sigma receptor agonist compound, AGY-94806, also known as M's Science compound SA4503, which AGY plans to study initially for enhancement of functional recovery after stroke.
http://biz.yahoo.com/prnews/040720/sftu022_1.html